Procyrion

Procyrion is a private, clinical-stage medical device company developing the Aortix™ device, a novel, minimally invasive circulatory pump for heart failure patients with cardioreal syndrome. Its technology is designed to be deployed percutaneously in under ten minutes to unload the heart and improve kidney perfusion, aiming to break the vicious cycle of cardiorenal syndrome. The company is currently conducting the pivotal DRAIN-HF study in the US and Eastern Europe, positioning it in a multi-billion dollar market with significant unmet need. Procyrion has garnered industry recognition, including being named to Fierce Medtech's Fierce15 list in 2023.

Aortix™ is a catheter-deployed, intra-aortic percutaneous mechanical circulatory support (pMCS) device. It uses a fluid entrainment mechanism to increase aortic flow, reducing cardiac afterload and increasing renal perfusion, specifically designed to treat acute decompensated heart failure and cardiorenal syndrome.

Procyrion competes in the percutaneous mechanical circulatory support (pMCS) market, which includes market leader Abiomed (Impella®). Aortix™ differentiates through its intra-aortic placement and fluid entrainment mechanism aimed at simultaneously unloading the heart and perfusing the kidneys, a unique value proposition targeted at cardiorenal syndrome. It may also face competition from other heart failure devices and pharmacological therapies.